Spots Global Cancer Trial Database for AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections
Official Title: Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load
Study ID: NCT01654822
Conditions
Study Description
Brief Summary: This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV) infection. * Primary endpoint: significant drop in viral load AV2-DM versus placebo * Secondary endpoint:the number of patients with adverse events
Detailed Description:
Eligibility
Minimum Age: 25 Years
Eligible Ages: ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Labo Riatol, Antwerpen, , Belgium
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
